Interestingly, although mock T cells exhibited antitumor activity against Capan-1 in a dose-dependent manner, CD155 CAR-T cells were far more potent, showing substantial tumor inhibition even at lower E/T ratios, where mock T cells had minimal effect (Figure 5D). This evidence concerns the gene PVR and neoplasm.